Efficiency of Original versus Generic Intravenous Iron Formulations in Patients on Haemodialysis

Maria Luisa Agüera1*, Alejandro Martin-Malo1*, Maria Antonia Alvarez-Lara1, Victoria Eugenia García-Montemayor2, Petra Canton2, Sagrario Soriano1, Pedro Aljama1

1 Servicio de Nefrología. Hospital Universitario Reina Sofía, Córdoba, Spain; Instituto Maimóndes de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Córdoba, Spain; RedInRen, Instituto de salud Carlos III, Spain, 2 Dialysis Unit, SOCODI SL, Córdoba, Spain

* These authors contributed equally to this work.

Abstract

Aims

The appropriate use of intravenous (IV) iron is essential to minimise the requirements for erythropoiesis-stimulating agents (ESAs). The clinical efficacy of generic IV iron compared to the original formulation is controversial. We evaluated the changes that were induced after switching from a generic IV iron to an original formulation in a stable, prevalent haemodialysis (HD) population.

Methods

A total of 342 patients were included, and the follow-up period was 56 weeks for each formulation. Anaemia parameters and doses of ESA and IV iron were prospectively recorded before and after the switch from the generic to the original IV iron.

Results

To maintain the same haemoglobin (Hb) levels after switching from the generic to the original formulation, the requirements for IV iron doses were reduced by 34.3% (from 52.8±33.9 to 34.7±31.8mg/week, p<0.001), and the ESA doses were also decreased by 12.5% (from 30.6±23.6 to 27±21μg/week, p<0.001). The erythropoietin resistance index declined from 8.4±7.7 to 7.4±6.7 IU/kg/week/g/dl after the switch from the generic to the original drug (p = 0.001). After the switch, the transferrin saturation ratio (TSAT) and serum ferritin levels rose by 6.8%(p<0.001) and 12.4%(p = 0.001), respectively. The mortality rate was similar for both periods.

Conclusions

The iron and ESA requirements are lower with the original IV iron compared to the generic drug. In addition, the uses of the original formulation results in higher ferritin and TSAT
levels despite the lower dose of IV iron. Further studies are necessary to analyse the adverse effects of higher IV iron dosages.

Introduction

Patients with chronic kidney disease (CKD) stage 5D on haemodialysis (HD) have increased mortality rates. This mortality risk is partly related to the severity of the patients’ anaemia, which has been associated with adverse clinical outcomes. Low haemoglobin (Hb) levels have been associated with higher mortality[1], increased cardiovascular events and reduced health-related quality of life in HD patients. However, randomised controlled trials have shown that normal Hb values are not associated with better survival [2, 3]. Therefore, the adequate management of anaemia is considered to be one of the most important factors in treating HD patients.

Anaemia, a common complication of CKD [4], has a complex pathogenesis and mainly arises due to inadequate erythropoietin production, insufficient iron storage, inflammation, vitamin B12 and folic acid depletion, severe secondary hyperparathyroidism and blood loss during the HD procedure. In CKD patients undergoing HD, anaemia was treated with blood transfusions prior to the introduction of recombinant erythropoiesis-stimulating agents (ESAs). However, recent clinical trials have reported controversial outcomes with regards to higher haematocrit levels [1–3] as well as high doses of ESAs[5, 6]. The Hb target level has consequently been lowered, decreasing the need for high doses of ESAs.

The use of intravenous (IV) iron to treat renal anaemia is currently increasing [7]. Under conditions of renal anaemia, the administration of iron is essential because absolute and functional iron deficiencies are common [8]. Because iron deficiencies must be corrected in order to increase Hb levels, moderate doses of ESAs should be administered to achieve the desired Hb levels [9–10]. However, the excessive and indiscriminate use of IV iron preparations can have insidious and serious adverse consequences, including iron overload [11], cardiovascular disease, immune deficiency and a potential increase in the risk of microbial infections[12].

The main side effects of IV iron are ascribed to the abrupt rise in serum levels of non-transferrin-bound iron (NTBI) [13]. NTBI causes the formation of reactive oxygen species (ROS), which damage the endothelium, promote endothelial dysfunction and cause inflammation [14]. Moreover, IV iron can lead to neutrophil [15] and monocyte dysfunction[16, 17]. The formulation of the administered iron is important for these effects [18]; in a previous study [17], we showed that a generic version of iron elicits a greater increase in ROS, intercellular adhesion molecule (ICAM)-1 and apoptosis than the original formulation.

Cost minimisation relies on the principle of substituting the original drugs with therapeutically equivalent alternatives and expecting equal outcomes at a reduced cost[19]. Generic drugs are usually less expensive than the original compound but must demonstrate bioequivalence [20] in order to be approved by regulatory authorities [21]. However, not all groups have shown that these products are clinically interchangeable with the original formulations[22].

Few studies have analysed the clinical outcomes after switching from the original formulation of IV iron to a generic drug. However, Rottembourg et al.[23] observed a reduction in Hb levels in patients who had been switched from the original to the generic IV iron formulation.

In April 2011, our HD centres switched the original formulation of IV iron-sucrose to a generic drug for economic reasons, and patients were followed to monitor for adverse events. Unexpectedly, in June 2012 (13 months later), a change in the price of the original formulation
prompted hospital administrators to revert back to the original IV iron formulation. Thus, we had the opportunity to prospectively follow patients who used the original IV iron formulation for an additional 13 months.

The principal aim of our study was to examine our prospectively collected data to analyse the effects of switching from generic IV iron-sucrose to the original formulation in a stable, prevalent population undergoing HD.

**Materials and Methods**

**Study design**

This observational and longitudinal repeated-measures study compared the same measurements that were collected prospectively before and after a switch from a generic IV iron to an original IV iron in a cohort of stable HD patients.

The study protocol is shown in Fig 1A. Beginning in April 2011, all of the patients were treated with the same generic formulation of IV iron along the study. In June 2012, the IV iron was changed to the original formulation and patients were followed for an additional 13 months. The data obtained from April 2011 to June 2012 were excluded because both medications may have been simultaneously available at the centre. The study was approved by the local ethics

---

Fig 1. Study design (1A) and algorithm of study population selection (1B).

doi:10.1371/journal.pone.0135967.g001
committee (Comité de la ética de la Investigación de Córdoba, Consejería de Salud; ref. 2645), and signed informed consent was obtained from patients before their inclusion in the study.

Study population
All of the prevalent, stable patients from our 7 HD centres from April 2011 to July 2013 were selected. All patients were dialysed using ultrapure dialysate fluid (<1 bacterial colony-forming unit/ml and <0.03 endotoxin units/ml). Residual renal function declined throughout the study, from 8.8% in the generic period to 5.6% in the original period (p = 0.031). However, weekly dialysis doses in terms of hours/week were similar during the 2 treatment periods (12.2 ± 0.15 in generic period vs. 12.5 ± 0.19 hours/week). Most patients were dialyzed 3 times per week, and the percentages of patients were similar between periods (92.1% of the population in generic period vs. 91.3% in original period). Eligible patients (Fig 1B) were those who treated with IV iron for at least 3 months before the formulation was switched (June 2012). The patients were censored if they received a kidney graft or died during the follow-up.

Treatment of anaemia: IV iron/erythropoiesis-stimulating agents
IV iron (generic or original) was administered during the HD session at a frequency ranging from once per month to up to twice per week. The ESA used was darbepoetinalfa, which was given intravenously during the mid-week dialysis session. The doses of IV iron and darbepoetinalfa were recorded at the beginning of each month throughout the 26 months of the study and were expressed as a weekly dose (mg per week for IV iron and μg per week for darbepoetinalfa). The doses of IV iron and ESA were adjusted for nightly to maintain the target Hb levels.

Study variables
The serum Hb, packed cell volume (PCV), ferritin levels, transferrin saturation ratio (TSAT), C-reactive protein (CRP) levels, adequacy of dialysis (eKt/V) and dry body weight were assessed monthly. Blood samples were collected before the dialysis session. If the participant had repeated measurements of any of these variables within a single month, the first measurement was used in the analysis. The erythropoiesis resistance index (ERI) was calculated as the ratio between the ESA dose, expressed in international units (translation rate 1:200) per kg body weight per week (IU/kg/week), and the Hb level (g/dl).

Statistical methods
The continuous data were expressed as the means ± standard deviation (SD) and median and interquartile range (IQR) for normal and skewed distributions, respectively. The categorical data were expressed as percentages. The data were logarithmically transformed when appropriate. Between-period comparisons (generic versus original period) were performed using the paired Student’s t-test and repeated-measures analysis of variance (ANOVA) for continuous data and either the McNemar test (χ²) or Cochran’s Q test for categorical data when appropriate. Statistical analyses were performed with Statistical Package for Social Sciences (SPSS) 12.0. Two-sided P values of less than 0.05 were considered statistically significant.

Results
Study population
Of the 553 prevalent adult patients on HD in Cordoba from April 2011 to July 2013, 342 were eligible for inclusion (Fig 1B). The study population was 59% male, with a mean age of 70±16 years. The main causes of end-stage renal diseases were diabetes (68 patients, 20% of the study
population), hypertension/vascular disease (37 patients, 11%) and glomerulonephritis (34 patients, 10%). The average dialysis duration was 89±71 months (Table 1).

Of the 342 study subjects, 271 remained on HD by the end of the study (79%), 55 patients died (16%) and 16 patients received a kidney transplant (5%) during the 26 months of follow-up. There was no significant difference in the mortality rate between periods (p = 0.183), and no adverse events were associated with switching from the generic to the original IV iron formulation.

**Treatment of anaemia: IV iron/ESA dose**

The mean dose of IV iron per patient was 52.8±33.9 mg/week during the Generic period and 34.7±31.8 mg/week during the Original period (p<0.001, Fig 2A), representing a 34.3% decrease. The mean dose of ESA was 30.6±23.6 μg/week during the Generic period and 27±21 μg/week during the Original period (p<0.001, Fig 2A), representing a 12.5% reduction.

**Parameters related to anaemia: Hb, ERI, TSAT and ferritin levels**

The Hb levels were stable throughout the study (26 months). The mean Hb level was 11.6±0.8 g/dl during the Generic period and 11.6±0.9 g/dl during the Original period (p>0.5, Fig 2A). The monthly data for IV iron dose, ESA dose and Hb levels throughout the study are shown in Fig 2B.

The variability in Hb, which was based on the distribution of the population within the 3 groups (below the target range, Hb<10 g/dl; within the target range, Hb = 10–12; or above the target range, Hb>12 g/dl), remained stable throughout the study. In both periods, 4% of patients had mean Hb levels below 10 g/dl (Fig 3A). In the quarterly study, there were no significant differences between quarters (Fig 3B). The PCV was also stable throughout the study.

The mean ERI level was 8.4±7.7 IU/kg/week/g per 100ml during the Generic period versus 7.4±6.7 IU/kg/week/g per 100ml during the Original period (p = 0.001), which constituted a 12% decrease. Based on the ERI level, the study population was divided into 3 groups: <5; between 5 and 15; and >15 (Fig 4A). 15.8% of patients had an ERI>15 during the Generic period compared with 10.7% during the Original period (p<0.001).

| Table 1. Baseline demographic and clinical characteristics of the study population (N = 342 patients). |
|---------------------------------------------------------------------------------------------------------------|
| Age, years (mean ± SD) | 70 ± 15.9 |
| Male, n (%) | 202 (59%) |
| Primary Renal Disease, n (%) |  |
| -Unknown | 120 (35.1%) |
| -Diabetes | 68 (19.9%) |
| -Hypertension | 37 (10.8%) |
| -Glomerulonephritis | 34 (9.9%) |
| -Tubulointerstitial Nephritis | 24 (7%) |
| -APKD | 24 (7%) |
| -Other Nephropathies | 35 (10.2%) |
| Vintage of HD, months (mean ± SD) | 89.5 ± 71.3 |
| BMI, Kg / m2 (mean ± SD) | 26.5 ± 6.1 |
| Charlson Index (mean ± SD) | 5.9 ± 2.3 |
| -Diabetes Mellitus, n (%) | 76 (22.3%) |
| -Myocardial Infarction, n (%) | 37 (11%) |
| -Heart Failure, n (%) | 44 (13%) |
| -Liver Disease, n (%) | 10 (3.2%) |

doi:10.1371/journal.pone.0135967.t001
The mean TSAT level increased by 6.8% between the Generic and Original periods (28.6 ±7.2% and 30.7±7.6%, respectively) (p<0.001). Based on the TSAT levels, the study population was divided into 4 groups: <20%; 20% to 25%; 26% to 30%; and >30% (Fig 4B). More patients were in the TSAT>30% group during the Original period than during the Generic period (48.2% versus 38%, respectively; p<0.001).

The serum ferritin levels also rose between the Generic and Original periods. The median ferritin levels (IQR) were 507 (338) mg/dl during the Generic period and 579 (393) mg/dl during the Original period (12.4% increase) (p = 0.001). These data were confirmed after the logarithmic transformation of the ferritin levels (data not shown).

![Figure 2](image-url)
Other variables

There were no significant differences in the dialysis doses (expressed as the bicomparti-
mental Kt/V), frequency and duration of HD sessions, type of dialysis membrane, number of blood
transfusions, serum CRP and albumin levels, or any other parameters between the Generic and
Original periods (data not shown).

Discussion

The administration of the original formulation of IV iron to a prevalent HD population
achieved the same Hb levels as the administration of the generic drug while using 34.3% less IV
iron and a 12.5% lower ESA dose. Despite the lower dose of IV iron, the levels of ferritin and
TSAT increased after the switch from the generic to the original IV iron formulation. These
results suggested that a change from the generic to the original iron formulation can be made
safely as long as the doses are adjusted according to the characteristics of the new formulation.
WHO guidelines promote the use of generic drugs as a strategy to mitigate high pharmaceutical prices [19]. Because generic and original drugs must demonstrate bioequivalence, one would expect that switching formulations would not be associated with any significant change in everyday clinical practices[21]. After a retrospective analysis of 2,070 single-dose clinical bioequivalence studies that were submitted to the United States Food and Drug Administration (FDA) from 1996 to 2007, Davit et al. [22] confirmed that the actual bioequivalence from the generic to original product is less than 10%. A meta-analysis by Kesselheim et al. [25] found that brand-name (original) drugs for cardiovascular disease were not superior to generic drugs. However, though no meta-analyses are available for other types of drugs (such as immunosuppressants[26] and antiepileptic medications), most studies have reported poorer results from the use of generic drugs compared to the original formulations.

For IV iron, few studies have previously compared the generic formulations to the original formulations in HD patients. Nonetheless, Rottenbourg et al. [23] used partial retrospective data obtained before and after the switch from the original to the generic formulation to compare the clinical and economic results of the two formulations. Our group has previously measured oxidative stress and apoptosis in blood samples from patients who were treated with

![Fig 4. Distribution of the population depending on ERI (4A) or TSAT levels (4B).](doi:10.1371/journal.pone.0135967.g004)
various iron compounds, including the generic and original iron-sucrose formulations [16]. Other groups have also developed a rat model to compare the effects of these formulations in vitro [27]. These studies suggest that generic compounds are more deleterious than the original versions.

The IV iron is used in patients on HD to treat renal anaemia. The current recommendation for renal anaemia treatment in patients on HD is the use of the lowest doses of IV iron and ESA necessary for achieving the desired target Hb level on an individual basis [9, 10]. In this study, switching from generic to original IV iron lowered the doses of both drugs (IV iron and ESA) without compromising Hb target levels during an ample (13 months) period of observation. The lower requirements for IV iron and ESA using the original IV iron formulation versus the generic formulation suggests that the former has a greater potency, which should be taken into consideration when analysing the outcomes and costs of the different treatments.

Patients on maintenance HD receive numerous therapeutic interventions, although the clinical benefits of these treatments are often uncertain. Since their development, ESAs have generally been used to avoid the need for blood transfusion. However, an association between the use of high doses of ESA and increased mortality has recently been reported [5, 6]. At present, the use of IV iron in combination with the lowest possible dose of ESA in controlling renal anaemia is increasing [28], thought the association between IV iron and serious adverse events [29] and mortality [30] remains unclear. Szczek et al. [31] suggested that using IV iron to reduce ESA doses could have important cardiovascular benefits, while Zitt et al. [32] found that the use of IV iron was associated with a 22% reduction in mortality. Moreover, Kalantar-Zadeh et al. [33] found that the risk of death was lower for patients on dialysis who received <400 mg of IV iron per month compared to patients receiving no IV iron. However, Feldman et al. [34] did not confirm an association between IV iron and mortality using techniques that account for changes in iron dosing and morbidity over time and Kshirsagar et al. [35] did also not find any association of IV iron to increased mortality. More recently, other authors [36, 37] have confirmed a similar mortality between patients on HD without iron and patients receiving “low” doses of iron. Both studies suggested an association between “high” doses of iron and mortality, describing high-dose of IV iron as 300 mg/month [36] or 1050 mg/3 months [37]. A randomised, controlled, open-label study designed to assess the effect of high-dose IV iron on mortality in HD patients (Proactive IV iron therapy in haemodialysis patients, PIVOTAL) [38] will be finished in 2017. In the interim, it seems recommendable to try to lower the dose of IV iron as much as possible. In the present study, we demonstrated a 34% reduction in the dose of IV iron after switching from the generic formulation to the original drug, suggesting that this change may decrease the high mortality rates of patients on HD.

Because the prices of the IV iron preparations were not uniform throughout our study, we could not make an adequate analysis of the costs. However, there was a significant decrease in the doses of ESA and IV iron required for maintaining the same Hb levels. Thus, our data suggest a cost-benefit to using the original formulation of IV iron rather than the generic formulation provided that both formulations have the same price.

The Hb variability responses to ESA may also result in adverse outcomes. We noted similar Hb variability levels [24] during the Generic and Original periods, which were confirmed in the quarterly analysis. During each period, only 4% of patients were below the target Hb range. Another study [23] reported more frequent out-of-range Hb levels when using the generic IV iron formulation versus the original.

Because the Hb levels remained stable and the doses of ESA were progressively reduced, the resulting ERI declined during the Original period. There is no consensus on the cut-off value at which ERI levels increase the mortality of HD patients. Some authors [39, 40] have analysed ERI in quartiles, while Nishio et al. [41] analysed the ERI in tertiles, and Lopez-Gomez et al.
[42] divided the population into 3 groups (<5; 5–15; and >15 IU/kg/week/g per 100ml). Regardless of the ERI cut-off, the mortality risk was higher in the patients with increased ERIs. In our study, after 56 weeks of follow-up, the mortality rates were similar between periods.

In our study, the ferritin and TSAT levels increased after the switch from the generic to the original IV iron formulation. Thus, the original IV iron is associated with higher levels of ferritin and TSAT despite being administered at lower doses than the generic formulation. This finding might be attributed to the difference in the kinetics of iron dissociation after changes in the stability of the core of the iron-sucrose complex [43]. Slight alterations in the manufacturing process of iron carbohydrates can result in disparities in the structure, molecular weight distribution and stability of the iron-oxyhydroxide core of the iron-sucrose complex [44]. Morphometric analyses in an animal model have revealed significantly less iron in its physiologically stored form, ferritin, after the administration of the generic formulation versus the original [27]. The deposition of iron in parenchymal tissues instead of the reticuloendothelial system might decrease the amount of iron that is available for effective erythropoiesis [45].

Other variables that could have an effect on anaemia control, such as CRP levels and the frequency and duration of dialysis, were similar between periods. Obviously, there was a possible carryover effect the first 3 months after switching from the generic formulation to original IV iron. However, we felt that the analysis of a long follow-up time (52 weeks) and the exclusion of patients who were lost before the third month could partially overcome this effect. In the statistical analysis, we included the entire study population (N = 342 patients), not just those who remained on haemodialysis at the end of the study (N = 271 patients). When the analysis was repeated for only the 271 patients who were alive on haemodialysis during both treatment periods, the results were similar to that of the entire study population.

The results of this study might be unable to be generalized to other original or generic IV iron formulations. Our recommendation is that the selection of a specific generic formulation should not be based solely on financial considerations, assuming comparable efficacy and safety, because original and generic formulations might not be interchangeable. Our particular generic IV iron formulation had a similar safety profile than the original—the mortality rates and potential clinical side effects were comparable—but disparate efficacy, because we had to adjust the dose of anaemia treatment. Based on our data, we strongly recommended that after changing a generic formulation of IViron to original IV iron, we must be aware of any changes in the parameters of anaemia to make appropriate dose adjustments for the treatment.

The main limitations of this study are inherent to its design. It is not a randomized double blind cross-over study. Although our repeated-measures design allowed us to control for many confounding factors, the data obtained from this observational, single-centre study might not be generalized to the rest of the HD population or to other Generic or Original IV iron formulations. Furthermore, the follow-up period was adequate for analysing the effects of the treatment on anaemia parameters, but it was not valid for evaluating the long-term outcomes associated with each formulation. High doses of ESAs[5,6] and IV iron [36, 37] and high ERI levels [39–42] have been linked to increased mortality in HD patients. In this study, we observed that the generic IV iron formulation is associated with higher ESA doses, higher IV iron doses and higher ERIs than the original IV iron formulation. Additional randomised controlled studies with longer follow-up periods must be designed to confirm our results.

In conclusion, the treatment of anaemia in HD patients with the original IV iron formulation requires lower doses of IV iron and ESAs than the generic iron formulation used in this study to achieve greater TSAT and serum ferritin levels and similarly stable Hb levels. Switching from the generic to the original IV iron formulation requires an adjustment in the dose of iron to maintain Hb levels within the target range.
Acknowledgments

We are grateful to J. Pastrana and R.I. Molina (Hospital Reina Sofia, Cordoba, Spain) for their technical assistance.

Author Contributions

Conceived and designed the experiments: MLA AMM. Performed the experiments: MLA AMM MAAL VEGM PC SS. Analyzed the data: MLA AMM MAAL PA. Contributed reagents/materials/analysis tools: VEGM PC. Wrote the paper: MLA AMM MAAL SS PA.

References

1. Locatelli F, De Francisco A, Deray G, Fliser D, Armstrong G, Dougherty FS, et al. Mortality and Cardiovascular Morbidity associated with Haemoglobin Levels: a pooled analysis of randomized controlled trials. Nephron Clin Pract 2014; 128: 323–332; doi: 10.1159/000366478
2. Jing Z, Wei-jie Y, Nan Z, Yi Z, Ling W. Hemoglobin Targets for Chronic Kidney Disease Patients with Anemia: A Systematic Review and Meta-analysis. PloS ONE 2012; 7 (8): e43655. doi: 10.1371/journal.pone.0043655 PMID: 22952731
3. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584–590; doi: 10.1056/NEJM199808273390903 PMID: 9718377
4. Stauffer me, Fan T. Prevalence of anemiae Chronic Kidney Disease in the United States. PLoS ONE 2014; 9 (1): e84943. doi: 10.1371/journal.pone.0084943 PMID: 24392162
5. Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Liu J, Winkelmaier WC. Comparative Mortality Risk of Anemia Management Practices in Incident Hemodialysis Patients. JAMA 2010; 303: 857–864; doi: 10.1001/jama.2010.206 PMID: 20197532
6. Koulouridis I, Alfayez M, Trikalinos TA, Balk EM, Jaber BL. Dose of Erythropoiesis-Stimulating Agents and Adverse Outcomes in CKD: A Meta-regression Analysis. Am J Kidney Dis 2013; 61 (1): 44–56; doi: 10.1053/ajkd.2012.07.014 PMID: 22921639
7. Freburger JK, Ng LJ, Bradbury BD, Kshirsagar AV, Brookhart MA. Changing patterns of anemia management in US hemodialysis patients. Am J Med 2012; 12, 909–914; doi: 10.1016/j.amjmed.2012.03.011
8. Gaweda AE, Ginzburg YZ, Chait Y, Germain MJ, Aronoff GR, Rachmilewitz E. Iron dosing in kidney disease: inconsistency of evidence and clinical practice. Nephrol Dial Transplant 2014; doi: 10.1093/ndt/gfu104
9. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guidelines for anaemia in chronic kidney disease. Kidney Int Suppl 2012; 2: 279–335; doi: 10.1038/kinsup.2012.37
10. Locatelli F, Bárány P, Covic A, de Francisco A, del Vecchio L, Goldsmith D, et al. ERA-EDTA ERBP Advisory Board Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 2013; 28: 1346–1359; doi: 10.1093/ndt/gft033 PMID: 23585588
11. Vaziri ND. Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis 2013; 61:992–1000; doi: 10.1053/ajkd.2012.10.027 PMID: 23375852
12. Rostoker G, Griuncelli M, Lordin C, Magna T, Janklewicz P, et al. Maximal Standard Dose of Parenteral Iron for Hemodialysis Patients: An MRI-Based Decision Tree Learning Analysis. PLoS ONE 2014; 9(12): e115096. doi: 10.1371/journal.pone.0115096 PMID: 25506921
13. Brissot P, Robert M, Le Lan C, Loréel O. Non-transferrin bound iron: a key role in iron overload and iron toxicity. BiochimBiophysActa2012; 1820: 403–410; doi: 10.1016/j.bbadis.2011.07.014
14. Pai AB, Conner T, McQuade CR, Olp J, Hicks P. Non-transferrin bound iron, cytokine activation and intracellular reactive oxygen species generation in hemodialysis patients receiving Intravenous iron dextran or iron sucrose. Biometals2011; 24:603–613; doi: 10.1007/s10534-011-9409-6 PMID: 21229380
15. Ichii H, Masuda Y, Hassanzadeh T, Saffarian M, Gollapudi S, Vaziri ND. Iron sucrose impairs phagocytic function and promotes apoptosis in polymorphonuclear leukocytes. Am J Nephrol 2012; 36: 50–57; doi: 10.1159/000339285
16. Fell LH, Zawada AM, Rogacev KS, Seiler S, Fliser D, Heine GH. Distinct immunologic effects of different Intravenous iron formulations on monocytes. Nephrol Dial Transplant 2014; 29: 809–832; doi: 10.1093/ndt/gft524 PMID: 24523357

17. Martin-Malo A, Merino A, Carracedo J, Álvarez-Lara MA, Ojeda R, Soriano S, et al. Effects of Intravenous iron on mononuclear cells during the haemodialysis session. Nephrol Dial Transplant 2012; 27: 2465–2471; doi: 10.1093/ndt/gfr711 PMID: 22207322

18. Connor JR, Zhang X, Nixon AM, Webb B, Perno JR. Comparative evaluation of Nephrotoxicity and Management by macrophages of intravenous pharmaceutical iron formulations. PLoS ONE 2015; 10 (5): e0125272; doi: 10.1371/journal.pone.0125272

19. Ramsey S. WHO Guideline on country pharmaceutical pricing policies. Recommendation 5.5 Promotion of the use of generic medicines. Geneva: World Health Organization. 2013. NBK258631

20. Van der Meersch A, Dechartres A, Ravaud P. Quality of Reporting of Bioequivalence Trials Comparing Generic to Brand Name Drugs: A Methodological Systematic Review. PLoS ONE 2011, 6(8): e23611. doi: 10.1371/journal.pone.0023611 PMID: 21858184

21. Dunne S, Shannon B, Dunne C, Cullen W. A review of the differences and similarities between Generic drugs and their originator counterparts, including economic benefits associated with usage of Generic medicines, using Ireland as a case study. BMC PharmacolToxicol 2013; 14: 1. doi:10.1186/2050-6511-14-1

22. Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT. Comparing Generic and Innovator Drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother 2009; 43 (10): 1583–97; doi: 10.1345/aph.1M141 PMID: 19776300

23. Rottembourg J, Kadri A, Leonard E, Dansaert A, Lafuma A. Do two Intravenous iron sucrose formulations have the same efficacy? Nephrol Dial Transplant 2011; 26: 3262–3267; doi:10.1093/ndt/gfr024 PMID: 21355067

24. Gaweda AD, Aronoff GR, Jacobs AA, Rai SN, Brier ME. Individualized Anemia Management Reduces Hemoglobin Variability in Hemodialysis Patients. J Am Soc Nephrol 2014; 25:159–166; doi: 10.1681/ASN.2013010089

25. Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, et al. Clinical equivalence of Generic and brand-name drugs used in Cardiovascular Disease. A systematic review and meta-analysis. JAMA 2008; 300 (21): 2514–2526; doi: 10.1001/jama.2008.758 PMID: 19050195

26. Harrison JJ, Schiffr JR, Coursol CJ, Daley CJ, Dipchand AI, Heywood NM, et al. Generic Immunosuppression in Solid Organ Transplantation: A Canadian Perspective. Transplantation 2012; 93: 657–665; doi: 10.1097/TP.0b013e3182445e9d PMID: 22267158

27. Toblli JE, Cao G, Oliveri L, Angerosa M. Comparison of oxidative stress and inflammation induced by different Intravenous iron sucrose similar formulations in a rat model. Inflamm Allergy Drug Targets 2012; 11: 66–78; doi: 10.2174/18715281279889358 PMID: 22309085

28. Fuller DS, Pisoni RL, Bieber BA, Port FK, Robinson BM. The DOPPS Practice monitor for US Dialysis Care: update on trends in anemia management 2 years into the bundle. Am J Kidney Dis 2013; 62; 1213–6. doi:10.1053/j.ajkd.2013.09.006 PMID: 24140369

29. Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, et al. Considerations and Challenges in Defining Optimal Iron Utilization in Hemodialysis. J Am Soc Nephrol 2015; 26: 1238–1247, 2015. doi:10.1681/ASN.2014090922

30. Zitt E, Sturm G, Kronenberg F, Neyer U, Knoll F, et al. Iron Supplementation and Mortality in Incident Dialysis Patients: An Observational Study. PLoS ONE 2014; 9(12): e114144. doi: 10.1371/journal.pone.0114144 PMID: 25462819

31. Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int 2015 Jun 17; doi: 10.1038/ki.2015.163 [Epub ahead of print].

32. Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, et al. Considerations and Challenges in Defining Optimal Iron Utilization in Hemodialysis. J Am Soc Nephrol 2015; 26: 1238–1247, 2015. doi:10.1681/ASN.2014090922

33. Szczec LA, Bamhart HX, Inrig JK, Reddan DN, Sapp S, et al. Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 2008; 74:791–798; doi:10.1038/ki.2008.295 PMID: 18596733

34. Zitt E, Sturm G, Kronenberg F, Neyer U, Knoll F, et al. Iron Supplementation and Mortality in Incident Dialysis Patients: An Observational Study. PLoS ONE 2014; 9(12): e114144. doi: 10.1371/journal.pone.0114144 PMID: 25462819

35. Kshirsagar AV, Freburger JK, Ellis AR, Wang L, Winkelwayer WC, et al. Intravenous Iron Supplementation Practices and Short-Term Risk of Cardiovascular Events in Hemodialysis Patients. PLoS ONE 2013; 8(11): e78930. doi: 10.1371/journal.pone.0078930 PMID: 24223866
36. Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, et al. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int 2015; 87: 162–8; doi: 10.1038/ki.2014.275 PMID: 25075769

37. Miskulin DC, Tangri N, Bandeen-Roche K, Zhou J, McDermott A, Meyer KB, et al. DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators. Intravenous Iron Exposure and Mortality in Patients on Hemodialysis. Clin J Am Soc Nephrol 2014; 9: 1930–9; doi: 10.2215/CJN.03370414

38. EU Clinical Trials Register: Proactive IV Iron Therapy for Haemodialysis patients (PIVOTAL), 2013. Available: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-002267-25/GB.

39. Panichi V, Rosati A, Bigazzi R, Paoletti S, Mantuano E, Beati S, et al. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant 2011; 26: 2641–2648; doi: 10.1093/ndt/gfq8002 PMID: 21325348

40. Rosati A, Tetta C, Merello Ji, Palomares I, Pérez-García R, Maduell R, et al. Cumulative iron dose and resistance to erythropoietin. J Nephrol 2014; doi: 10.1007/s40620-014-0127-3

41. Nishio A, Chhatkuli BP, Ma JZ, Kalantari K. Higher Doses of Erythropoietin-Stimulating Agents and Hyporesponsiveness to Their Effects are associated with increased mortality among prevalent hemodialysis patients. Blood Purif 2013; 36: 29–36; doi: 10.1159/000350583 PMID: 23735569

42. López-Gómez JM, Portoles JM, Aljama P on behalf of the MAR Study Group. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int Suppl 2008; 74: S75–81; doi: 10.1038/ki.2008.523

43. Slotki I, Cabantchik ZI. The Labile Side of Iron Supplementation in CKD. J Am Soc Nephrol. 2015 May 21. doi: 10.1681/ASN.2015010052 [Epub ahead of print]

44. Schellekens G, Klinger E, Mühlebach S, Brin JF, Storm G, Crommelin DJA. The therapeutic equivalence of complex drugs. Regul Toxicol Pharmacol 2011; 59: 176–183; doi: 10.1016/j.yrtph.2010.09.021

45. Fishbane S, Mathew A, Vaziri ND. Iron toxicity: relevance for dialysis patients. Nephrol Dial Transplant 2014; 29: 255–259; doi: 10.1093/ndt/gft269 PMID: 24166458